Details for New Drug Application (NDA): 019806
✉ Email this page to a colleague
The generic ingredient in SEMPREX-D is acrivastine; pseudoephedrine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the acrivastine; pseudoephedrine hydrochloride profile page.
Summary for 019806
Tradename: | SEMPREX-D |
Applicant: | Endo Operations |
Ingredient: | acrivastine; pseudoephedrine hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 8MG;60MG | ||||
Approval Date: | Mar 25, 1994 | TE: | RLD: | Yes |
Expired US Patents for NDA 019806
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Endo Operations | SEMPREX-D | acrivastine; pseudoephedrine hydrochloride | CAPSULE;ORAL | 019806-001 | Mar 25, 1994 | ⤷ Subscribe | ⤷ Subscribe |
Endo Operations | SEMPREX-D | acrivastine; pseudoephedrine hydrochloride | CAPSULE;ORAL | 019806-001 | Mar 25, 1994 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription